Canada markets open in 2 hours 38 minutes

CloudMD Software & Services Inc. (DOC.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
2.0600-0.0600 (-2.83%)
At close: 3:59PM EDT
Sign in to post a message.
  • M
    Ive been holding shares for a few months now and decided to use the service for the first time today. I work in construction and have long days so being able to get a prescription while at work today was awesome! Service was great, super easy to set yourself up and book an appointment within minutes.

    At the end of the video call I asked the doctor what her thoughts were on telehealth and she mentioned it changed her life as a doctor for the better.

    My original reason for investing was not only because I viewed the business activities positively, but also how telehealth simply makes lives better. My appointment today reassured my investment and I am excited to be an owner of the stock.

    Holding 5180 @ 2.20
  • J
    Jack Mayhoffer
    Canaccord Roadshow Notes

    DOC-TSXV | Price C$2.12 | Market Cap C$578.2M
    PRICE TARGET C$3.50 Unchanged

    Investment Recommendation
    We are maintaining our SPECULATIVE BUY rating on CloudMD and our $3.50 target price after hosting a day of investor meetings with CEO Dr. Essam Hamza and CFO Daniel Lee. Management touted the benefits of the broad portfolio of healthcare assets it has rapidly assembled in recent months, noting that the combined assets are gaining traction with employers looking for a holistic approach to employee health. This has been evidenced by the strong organic growth in the Enterprise Health Solutions unit so far in 2021 ($5M+ in bookings) – this area continues to draw increased investor focus given the long-term implications on predictability, margins and multiple.

    Investment Highlights
    Enterprise Health remains a focus item for both management and investors. As we highlighted with Q4 results, the company has re-segmented its financial disclosure to draw the eye to what will become a much more substantial proportion of DOC’s business: Enterprise Health Solutions. On a proforma basis, once the announced acquisitions are closed, this will represent ~$53M or ~44% of the $120M overall revenue run-rate. This unit features higher organic growth, higher predictability, and margins (already 10%+ EBITDA) and we think the additional detail provided on this unit over time has positive implications for valuation.
    Paid trial an example of momentum with this combined offering. As an example of the kind of uptake that CloudMD is seeing with its Enterprise Health unit, the company noted that a large employer (13,000 employees) began a 6-month paid trial last week which is based on the combined suite of products. The company indicated that it has already received positive feedback from its customer, suggesting a high probability of converting the pilot into a longer-term contract upon completion.
    Increased discussion on margins. Following a period of focus on consolidation, we have observed an increased focus on what the margin profile looks like post consolidation for companies like CloudMD. Management said it targets achieving a margin of 10% in the medium term, while reinvesting the excess profits in sustaining growth. In a more mature market, the company expects margins could approach 15%+. As a reminder, the company recently confirmed it expects to become EBITDA profitable in Q3/21 and current consensus is for EBITDA margins of 7% in 2022E.
    No change to our recently updated estimates. We refreshed our model last week to reflect the updated segmentation and outlook provided by management (see our recent note here) but with little change to our overall estimates as we see increased stability in forecasts with the increased scale that DOC possesses. As such, we are not changing our estimates today, pending Q1 results in the coming month. The company has spoken to a $120M+ proforma revenue run-rate, and is adding to it with organic revenue growth, supporting our model of $141M in revenue in 2022. Our full model is presented in Figure 1.
    As we had recently rolled forward our model alongside Q4/F2020 results, our valuation is largely unchanged. Our $3.50 target price equates to 6.5x NTM+1 EV/Sales ending December 2022. At current prices, DOC shares reflect 3.8x 2022E revenue and 48.0x EBITDA, a discounted valuation vs. healthcare technology and hybrid healthcare peers.
  • s
    500k traded without moving the stock. Strong base?
  • D
    Alrighty bored friends....the CloudMD sweepstakes....your prize...baller rights!

    What comes next before Q1 in 3.5 weeks time? Choose A, B, C, D, E
    a) Uplist Formal Notice(Company stated June so we are close and usually its around 6 week process from GO)
    b) New Enterprise(EHS) biggy deal
    c) Next Provence Announced - Al or Quebec
    d) Closing of VisionPros
    e) All of the above
  • S
    The hardest part of investing is not buying and selling, it's patiently holding. DOC has traded in a relatively narrow range between $2-3 for 8 months, so many investors have given up, sold, and moved on. There were many times when I was a new investor where I became impatient and sold shares of a company whose share price was stagnant, and a few months after I sold they skyrocketed upwards. Learn the skill of patience and you will become wealthy, I guarantee it.
  • D
    Loved this quote for expectations from the Q4 report further below from Dr Hamza:

    “I am proud that we have seen healthy organic growth across all verticals of our business despite the long closures due to COVID-19. As we see communities starting to re-open, in addition to the majority of the acquisitions closing in first quarter 2021 and the roll out of our fully connected healthcare ecosystem, we expect to see significant revenue growth in the upcoming quarters.”

    Dr. Essam Hamza, CEO of CloudMD commented, “I am very pleased with our fourth quarter and full year 2020 financial results which are consistent with our internal and consensus estimates. The fourth quarter was a foundation-building quarter for CloudMD with the completion of five strategic acquisitions and the launch of our Enterprise Health Solutions Division. I am proud that we have seen healthy organic growth across all verticals of our business despite the long closures due to COVID-19. As we see communities starting to re-open, in addition to the majority of the acquisitions closing in first quarter 2021 and the roll out of our fully connected healthcare ecosystem, we expect to see significant revenue growth in the upcoming quarters.” Dr. Hamza continued, “We have a current revenue run rate of over $120 million, which does not account for any of the organic growth and cross selling synergies we are anticipating this year. In addition, we are also expecting to be Adjusted EBITDA-positive in the latter half of 2021 with healthy gross margins. We are well-positioned as leaders in the digital healthcare space and I am very excited to see the continued growth of our business in 2021.”
  • J
    Q1 coming soon, TSX up listing coming soon, Profitable by Q3 of 2021, 120 revenue run rate for 2021 not including organic growth and cross selling, #1 on purpose Canadian equity growth fund, expansions into Europe. Waiting on Alberta and Quebec to get on board and believe me they will along with the rest of canada. This is just the beginning folks.
  • P
    We deserve and are due a good breakout, and I see it happening in the next 60 days.
  • T
    CloudMD is turning profit faster than Teladoc.

    Hmm. Wow.
  • d
    Market dives into the abyss and DOC barely flinches… it
  • J
    Truth is, great things take time, So, either you wait or you settle for less.
  • J
    My average is $2.008 on the shares I own. Let's say it doesn't hit 3.50$ until Dec 2022. For me that's a 75% return in under 2 years. If you can do better please teach me.
  • S
    DOC continues to be the strongest performer in the telehealth sector. Day after day.
  • Q
    I used cloudMD for the first time this weekend. I did wait 20 minutes for my appointment but it took 2 minutes to ask for a doctors note …. Plus I was just walking around Canadian Tire! Very convenient :)
  • T
    Introducing iMD's new partner St. Joseph's Care Group!

    SJGC and iMD partner to make it easier for clients, families, and staff to find up-to-date resources and information on various healthcare topics.
  • S
    LOLLLLLLL Doc is stable, just waiting for 2.5 weeks - Q1 Earnings and potential guidance on uplist. Down 1$ and Dill and Anonymous are having a love fest LMAO! They must be cousins!
  • D
    was that a large TUTE buy at 10.18 PDT?......tea is brewing....
  • D
    I have never seen the shorts posting so much. They are doing everything they can do drive down the price. I feel they are desperate and in trouble. They must need to cover prior to Q1 ernings
  • S
    Strictly speaking from a technical analysis perspective, we’re seeing a Ascending Triangle pattern in the hourly time frame. Should see a breakout to $2.26 and higher in the next few days.
  • m
    The cloud MD app is now live on the save-on-foods website.